This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Benfotiamine is a derivative of thiamine thought to be useful in the management of diabetic neuropathy, although evidence is lacking.
- Generic Name
- Benfotiamine
- DrugBank Accession Number
- DB11748
- Background
Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Benfotiamine (DB11748)
- Weight
- Average: 466.45
Monoisotopic: 466.107592649 - Chemical Formula
- C19H23N4O6PS
- Synonyms
- Benfotiamina
- Benfotiamine
- Benphothiamine
- Benzoylthiamine monophosphate
- S-benzoylthiamine monophosphate
- External IDs
- 8088 C.B.
- 8088-CB
- 8088CB
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image MILGAMMA MONO 150 Tablet, coated 150 mg Oral บริษัท ซิลลิค ฟาร์มา จำกัด 2018-06-18 Not applicable Thailand 
Categories
- ATC Codes
- A11DA03 — Benfotiamine
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y92OUS2H9B
- CAS number
- 22457-89-2
- InChI Key
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N
- InChI
- InChI=1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-
- IUPAC Name
- {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid
- SMILES
- C\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1
References
- General References
- Worwag Pharma: Milgamma Protekt (benfotiamine) film-coated tablets [Link]
- External Links
- PubChem Compound
- 3032771
- PubChem Substance
- 347828105
- ChemSpider
- 2297665
- 18891
- ChEBI
- 41039
- ChEMBL
- CHEMBL4303665
- ZINC
- ZINC000002015559
- Wikipedia
- Benfotiamine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Endothelial Dysfunction / Type 2 Diabetes Mellitus 1 4 Completed Treatment Alcohol Dependency 1 4 Completed Treatment Diabetic Nephropathy 1 4 Unknown Status Prevention Type 2 Diabetes Mellitus 1 3 Completed Prevention Healthy Subjects (HS) 1 3 Unknown Status Treatment Diabetic Neuropathies 1 2 Completed Treatment Alzheimer's Disease (AD) 1 1, 2 Completed Treatment Type 1 Diabetes Mellitus 1 1, 2 Withdrawn Treatment Painful Diabetic Neuropathy (PDN) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 150 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.04 mg/mL ALOGPS logP 0.89 ALOGPS logP -2.2 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 0.71 Chemaxon pKa (Strongest Basic) 7.37 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 155.94 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 121.54 m3·mol-1 Chemaxon Polarizability 43.14 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at October 20, 2016 20:44 / Updated at May 07, 2021 21:07